Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 20 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

10%

2 trials in Phase 3/4

Results Transparency

6%

1 of 18 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

19Total
Not Applicable (1)
P 1 (4)
P 2 (12)
P 4 (2)

Trial Status

Completed18
Unknown1
Enrolling By Invitation1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 18 completed trials

Clinical Trials (20)

Showing 20 of 20 trials
NCT07215871Phase 1Enrolling By Invitation

Rechallenge With a Low Pathogenicity Avian H10N7 Influenza Virus in Healthy Human Volunteers Previously Challenged With H10N7 Influenza

NCT05422326Phase 2Completed

A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed

NCT03294473Not ApplicableCompleted

Centralized Reminder Recall - Flu RCT2

NCT03392207Completed

Active Surveillance for Adverse Events Following Immunization With the Butantan Trivalent Influenza Vaccine (2018)

NCT00755274Phase 4Completed

Annual Study for Serum Collection for Immunogenicity and Safety Evaluation in Healthy Children Receiving Fluzone®

NCT01587131Phase 1Completed

DNA-based Influenza Vaccine in the Elderly

NCT00491257Phase 2Completed

A Study of the Immunogenicity and Safety of the 2007-2008 Influenza Vaccine

NCT00718146Phase 2Completed

Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation

NCT00343681Phase 2Completed

A Study of the Immunogenicity and Safety of the 2006-2007 Influenza Vaccine

NCT00457509Phase 1Completed

Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults

NCT00415129Phase 2Completed

Safety and Immunogenicity of an Intramuscular Pandemic Influenza Vaccine in Adults and the Elderly

NCT00545701Phase 2Completed

Immunogenicity and Safety of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Adults

NCT00258934Phase 2CompletedPrimary

Immunogenicity Study of the Influenza Vaccine in Adults

NCT00606359Phase 2Completed

Immunogenicity of the Inactivated Split-Virion Influenza Vaccine in Renal Transplant Subjects

NCT00884182Phase 2Completed

Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Children

NCT00491985Phase 2Completed

Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in Children

NCT01842997Phase 4Completed

Safety of H1N1 Influenza Vaccination in Pregnant Women

NCT00975572Phase 2Completed

Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Population Aged 3 Years and Older

NCT00664417Phase 1Completed

Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine

NCT01055990Phase 2Unknown

Basic and Clinical Research on Applying Blood Fix to Treat Critical H1N1 Patients

Showing all 20 trials

Research Network

Activity Timeline